This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Boccia, R. Articles by Silberstein, P. Search for Related Content PubMed PubMed Citation Articles by Boccia, R. Articles by Silberstein, P.

Symptom Management and Supportive Care

Darbepoetin Alfa Administered Every Three Weeks Is Effective for the Treatment of Chemotherapy-Induced Anemia

^a Georgetown University/Center for Cancer and Blood Disorders, Bethesda, Maryland, USA; ^b Loma Linda University Medical Center, Loma Linda, California, USA; ^c Bond Clinic, Rolla, Missouri, USA; ^d Sioux Land Regional Cancer Center, Sioux City, Iowa, USA; ^e Hawaii Pacific Health at Straub Clinic and Hospital, Honolulu, Hawaii, USA; ^f Amgen Inc., Thousand Oaks, California, USA; ^g Santee Hematology/Oncology Inc, Sumter, South Carolina, USA; ^h Creighton University Medical Center, Omaha, Nebraska, USA

Key Words. Chemotherapy • Anemia • Darbepoetin alfa • Hemoglobin • Cancer

Correspondence: Peter Silberstein, M.D., Creighton University Medical Center, 601 North 30th Street, Suite 2565, Omaha, Nebraska 68131, USA. Telephone: 402-280-3432; Fax: 402-280-4638; e-mail: PeterSilberstein{at}creighton.edu

Patients with cancer receiving chemotherapy often have chemotherapy-induced anemia (CIA) and reduced quality of life. Darbepoetin alfa can effectively treat CIA when administered at an extended dosing interval of once every 3 weeks (Q3W). Darbepoetin alfa administered Q3W may allow synchronization of darbepoetin alfa therapy with chemotherapy administered Q3W. This multicenter, open-label, 16-week study evaluated the effectiveness and safety of darbepoetin alfa administered as a fixed dose (300 µg) Q3W in patients with CIA. Eligible patients (18 years) were anemic (hemoglobin <11g/dl), had a nonmyeloid malignancy, and were receiving multicycle chemotherapy. This analysis includes 1,493 patients who received at least one dose of darbepoetin alfa. The effect of baseline hemoglobin (<10 or 10 g/dl) on clinical outcomes was evaluated. Patients in the 10-g/dl stratum achieved the hemoglobin target range (11–13g/dl)in less time than patients in the <10-g/dlstratum (3 weeks vs. 9 weeks). More patients in the 10-g/dl stratum achieved the hemoglobin target range (87% vs. 66%); however, similar proportions of patients in both strata maintained hemoglobin within the target range (73% vs. 71%). Fewer patients in the 10-g/dl stratum received RBC transfusions from week 5 to the end of the study (12% vs. 28%). Over 50% of patients in both strata reported clinically significant improvements (3-point increase) in Functional Assessment of Cancer Therapy–Fatigue score. Twenty-eight percent of patients reported serious adverse events; 3% of all patients had a venous or arterial thrombotic event. This study demonstrates that darbepoetin alfa Q3W is well tolerated and effective for treating CIA.

This article has been cited by other articles:

				S. Al-Majid and D. P. Gray A Biobehavioral Model for the Study of Exercise Interventions in Cancer-related Fatigue Biol Res Nurs, April 1, 2009; 10(4): 381 - 391. [Abstract] [PDF]

				R. Pirker, R. A. Ramlau, W. Schuette, P. Zatloukal, I. Ferreira, T. Lillie, and J. F. Vansteenkiste Safety and Efficacy of Darbepoetin Alfa in Previously Untreated Extensive-Stage Small-Cell Lung Cancer Treated With Platinum Plus Etoposide J. Clin. Oncol., May 10, 2008; 26(14): 2342 - 2349. [Abstract] [Full Text] [PDF]

				S. S Shord, J.M. Hamilton Jr, and S. Cuellar Parenteral iron with erythropoiesis-stimulating agents for chemotherapy-induced anemia Journal of Oncology Pharmacy Practice, March 1, 2008; 14(1): 5 - 22. [Abstract] [PDF]

				R. J. Muller and D. Baribeault Extended-dosage-interval regimens of erythropoietic agents in chemotherapy-induced anemia Am. J. Health Syst. Pharm., December 15, 2007; 64(24): 2547 - 2556. [Abstract] [Full Text] [PDF]

				V. Charu, B. Saidman, A. Ben-Jacob, G. R. Justice, A. S. Maniam, D. Tomita, G. Rossi, T. Rearden, and J. Glaspy A Randomized, Open-Label, Multicenter Trial of Immediate Versus Delayed Intervention with Darbepoetin Alfa for Chemotherapy-Induced Anemia Oncologist, October 1, 2007; 12(10): 1253 - 1263. [Abstract] [Full Text] [PDF]

				R. Boccia, T. Lillie, D. Tomita, and L. Balducci The Effectiveness of Darbepoetin Alfa Administered Every 3 Weeks on Hematologic Outcomes and Quality of Life in Older Patients With Chemotherapy-Induced Anemia Oncologist, May 1, 2007; 12(5): 584 - 593. [Abstract] [Full Text] [PDF]